We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.
- Authors
Ottmann, Oliver G.; Müller‐Tidow, Carsten; Krämer, Alwin; Schlenk, Richard F.; Lübbert, Michael; Bug, Gesine; Krug, Utz; Bochtler, Tilmann; Voss, Florian; Taube, Tillmann; Liu, Dan; Garin‐Chesa, Pilar; Döhner, Hartmut
- Abstract
The article presents the phase one results of a study on volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (AML). Topics discussed include dose escalations and dose-limiting toxicities, most common treatment-related adverse events (AEs,) and safety profile of volasertib in AML patients.
- Subjects
CYTARABINE; MATHEMATICAL combinations
- Publication
British Journal of Haematology, 2019, Vol 184, Issue 6, p1018
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.15204